DX
Disease Management, Mechanisms, and Treatment (Platform/Oral)
Friday, May 30, 2014: 1:00 PM-3:00 PM
Coronado B
1:00 PM
Disability Progression in Multiple Sclerosis Patients in the Tysabri® (Natalizumab) Observational Program (TOP)
Fabio Pellegrini, MSc Stat, Consorzio Mario Negri Sud;
Helmut Butzkueven, MBBS, PhD, University of Melbourne;
Ludwig Kappos, MD, University Hospital Basel;
Maria Trojano, MD, University of Bari;
Heinz Wiendl, MD, University of Münster;
Annie Zhang, BM, MPH, Biogen Idec Inc.;
Shibeshih Belachew, MD, PhD, Biogen Idec Inc.
1:20 PM
Relapsing–Remitting Multiple Sclerosis Treated with Interferon Beta-1a: Immunological and Short-Term Brain Volume Changes
Michael G. Dwyer, PhD, State University of New York at Buffalo;
Robert Zivadinov, MD, PhD, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center;
Yazhong Tao, PhD, University of North Carolina at Chapel Hill;
Xin Zhang, MD, University of North Carolina at Chapel Hill;
Cheryl Kennedy, LMSW, MPH, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center;
Niels Bergsland, MS, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center;
Deepa P Ramasamy, MD, State University of New York at Buffalo;
Jacqueline Durfee, BSc, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center;
David Hojnacki, MD, University at Buffalo;
Bianca Weinstock-Guttman, MD, University at Buffalo;
Brooke Hayward, SM, MBA, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.;
Silva Markovic-Plese, MD, University of North Carolina at Chapel Hill
1:40 PM
No Evident Disease Activity (NEDA): Associations with Brain Atrophy and Functional Outcomes in Patients from the Affirm Study
Richard R Rudick, MD, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation;
Elizabeth Fisher, PhD, Cleveland Clinic Foundation;
Andrew Goodman, MD, University of Rochester;
Fred D. Lublin, MD, The Icahn School of Medicine at Mount Sinai;
J. Theodore Phillips, MD, PhD, FAAN, Multiple Sclerosis Program, Baylor Institute for Immunology Research;
Amy Pace, ScD, Biogen Idec Inc.;
Shibeshih Belachew, MD, PhD, Biogen Idec Inc.
2:00 PM
Immunogenicity with Peginterferon Beta-1a: 2-Year Data from the ADVANCE Study in Relapsing-Remitting Multiple Sclerosis
Scott D Newsome, D.O., Johns Hopkins University;
Bernd C Kieseier, MD, Heinrich-Heine University;
Joleen T White, PhD, Biogen Idec Inc.;
Ying Zhu, PhD, Biogen Idec Inc.;
Yue Cui, PhD, Biogen Idec Inc.;
Ali Seddighzadeh, MD, Biogen Idec Inc.;
Serena Hung, MD, Biogen Idec Inc.;
Aaron Deykin, MD, Biogen Idec Inc.;
Meena Subramanyam, PhD, Biogen Idec Inc.
2:20 PM
Immunological Markers and Conventional and Advanced MRI after Interferon Beta-1a for Relapsing–Remitting Multiple Sclerosis
Silva Markovic-Plese, MD, University of North Carolina at Chapel Hill;
Yazhong Tao, PhD, University of North Carolina at Chapel Hill;
Xin Zhang, MD, University of North Carolina at Chapel Hill;
Michael G. Dwyer, PhD, Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York at Buffalo;
Cheryl Kennedy, LMSW, MPH, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center;
Niels Bergsland, MS, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center;
Deepa P Ramasamy, MD, State University of New York at Buffalo;
Jacqueline Durfee, BSc, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center;
David Hojnacki, MD, State University of New York at Buffalo The Jacobs Neurological Institute;
Bianca Weinstock-Guttman, MD, State University of New York at Buffalo;
Brooke Hayward, SM, MBA, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.;
Robert Zivadinov, MD, PhD, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center
2:40 PM
Disability Progression after Switching from Natalizumab to Fingolimod or Injectable Therapies: A NARCOMS Analysis
Stacey S Cofield, PhD, University of Alabama at Birmingham;
Robert J Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic;
Tuula Tyry, PhD, Barrow Neurological Institute of Saint Joseph's Hospital and Medical Center;
Amber R Salter, MPH, University of Alabama at Birmingham;
Denise Campagnolo, MD, Biogen Idec Inc.;
Mary-Jean Fanelli, MD, MBA, Biogen Idec Inc.;
Terrie Livingston, MD, Biogen Idec Inc.
